MCCAIG It has been less than a month since my last Novavax (NASDAQ:NVAX) article, where I discussed partnership with Sanofi (SNY) and updates on their COVID-19 and H5N1 bird flu vaccine programs. Those updates forced me to revise my NVAX strategy to account for upcoming catalysts and the possibility of a sustained rally. Well, that rally turned into a malaise fade over the past few weeks. However, the ticker has experienced a shot of volatility over the past few trading sessions after the company released t ...

Novavax Inc. NASDAQ: NVAX is a biotechnology company that focuses on developing and commercializing vaccines for serious infectious diseases. Its most significant vaccine, Nuvaxovid, is for COVID-19. The hype surrounding the potential for Nuvaxovid drove Novavax shares as high as $331.68 in February 2021. However, the reality of missteps resulting in being “late to the party” caused shares to crater to $3.53 by February 2024. Shares have since surged as high as $23.86 in June 2024 on a $1.2 billion licensin ...

Novavax (NVAX) posted earnings per share of 99 cents in second-quarter 2024, missing the Zacks Consensus Estimate of $1.82. However, earnings rose 71% year over year.Revenues in the quarter amounted to $415.5 million, also missing the Zacks Consensus Estimate of $453.7 million. The top line declined 2% on a year-over-year basis.Quarter in DetailIn the reported quarter, the company recorded $19.9 million in product sales compared with $285.2 million in the year-ago quarter. While this reported figure did bea ...

Novavax (NVAX) came out with quarterly earnings of $0.99 per share, missing the Zacks Consensus Estimate of $1.82 per share. This compares to earnings of $0.58 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -45.60%. A quarter ago, it was expected that this vaccine maker would post a loss of $1.04 per share when it actually produced a loss of $1.05, delivering a surprise of -0.96%.Over the last four quarters, the company has s ...

Achieved total revenue of $415 million in the second quarter of 2024 and ended the period with $1.1 billion in Cash Filed with the U.S. FDA and EMA for authorization of updated 2024-2025 formula COVID-19 vaccine Received $570 million in upfront payment and equity investment from Sanofi; progressed operationalization of Sanofi partnership Phase 3 trial initiation for COVID-19-Influenza Combination and stand-alone influenza vaccines planned for Q4 2024; data expected by mid-2025 Company to host conference ca ...

COVID-19疫苗开发与生产 - 公司正在开发更新版COVID-19疫苗NVX-CoV2705,并已向美国FDA、欧洲EMA、英国MHRA和加拿大卫生部提交申请[161] - 公司正在开发COVID-19和流感联合疫苗候选药物,以及独立的季节性流感疫苗候选药物,计划于2024年第四季度启动III期临床试验[164] - 公司的重组计划包括更加专注于COVID-19疫苗项目,包括原型疫苗NVX-CoV2373、变异株疫苗NVX-CoV2601和更新版NVX-CoV2705[24] - 公司正在努力扩大COVID-19疫苗在不同年龄人群的适用范围,并推动各国政府和监管机构的政策支持[173] - 公司的COVID-19疫苗在美国的生物制品许可申请已被FDA受理,预计2025年4月做出审批决定[162] - 公司正在寻求全球范围内对2024-2025年配方的JN.1 COVID疫苗的授权[174] - 公司正在进行临床试验以扩大COVID-19疫苗在青少年和儿童适应症的适用范围[177] - 公司预计将在2024-2025疫苗接种季节开始前向市场提供更新后的COVID-19疫苗[192,193] 疫苗技术平台与合作 - 公司的基于蛋白质的纳米颗粒疫苗技术和专有的Matrix-M佐剂有利于开发针对呼吸道和新发传染病的疫苗候选药物[166,167,168] - 公司的Matrix-M佐剂正被用于其他公司开发的疫苗,如疟疾疫苗R21/Matrix-M和其他预临床项目[169,170] - 公司与赛诺菲签订合作协议,共同开发和销售COVID-19疫苗,包括未来针对季节性变异株的更新版疫苗[163] - 公司与Sanofi签署合作协议,Sanofi将从2025年1月1日起负责公司2024-2025年配方COVID-19疫苗在美国、欧洲和其他主要市场的主要商业化责任[186] 财务表现 - 2024年第二季度总收入为5.09亿美元，同比增长0.8%[226] - 2024年第二季度产品销售收入为1.02亿美元，同比下降63.2%[226,228] - 2024年第二季度许可、版税和其他收入为4.07亿美元，同比增长12.6倍[226,232] - 2024年第二季度研发费用为1.07亿美元，同比下降51.3%[215,216,217] - 2024年第二季度销售、一般及管理费用为1.01亿美元，同比增长8.1%[218] - 2024年第二季度净利润为1.62亿美元，同比增长79.9%[223,224] - 研发费用从2023年上半年的4.666亿美元下降到2024年上半年的1.996亿美元,主要是由于与冠状病毒疫苗开发活动相关的支出减少[236][237] - 销售、一般及管理费用从2023年上半年的2.062亿美元下降到2024年上半年的1.881亿美元,主要是由于采取了某些成本控制措施来减少运营支出[238] - 2024年上半年的净利润为1483万美元,而2023年上半年为净亏损2.359亿美元,主要是由于研发费用的减少[242][243] 重组与成本控制 - 公司正在优化组织架构,集中资源于与赛诺菲的合作过渡、III期联合疫苗和独立流感疫苗项目以及更新版COVID-19疫苗的交付[165] - 公司正在进行成本削减计划,以创建更精简和敏捷的组织,并加快研发重点[190,191] - 公司正在采取重组和成本削减措施,并可能通过额外的股权和债务融资、合作、战略联盟等方式筹集资金[245][246] 合同变更与风险 - 公司与澳大利亚政府签订的疫苗采购协议可能会因为无法及时获得监管批准而导致合同金额减少2.4亿美元[256] - 公司与新西兰政府的APA合同被终止,可能损失约1.25亿美元的合同价值[257] - 与加拿大政府的APA合同可能被终止,约2.24亿美元的合同价值可能不再可用[258] - 与英国政府的疫苗供应协议被修订,公司需要偿还1.125亿美元的预付款[260][261] - 与Gavi的APA合同被终止,公司需支付4.75亿美元的和解款[262][263] - 公司面临汇率波动风险,10%汇率下跌可能导致股东权益减少5,720万美元[274][275] 其他 - 公司正在继续优化前期候选疫苗,包括RSV疫苗和新型H5N1禽流感疫苗[175] - 公司正在评估Matrix-M™佐剂增强新旧疫苗免疫反应的潜力[175] - 公司与FDA互动,为联合流感和单独流感疫苗候选产品的III期临床试验做准备[180,181] - 公司通过股票发行和与Sanofi的股票认购协议筹集了资金[195,196,198] - 公司获得CEPI的无息贷款支持,未来销售收入可用于偿还贷款[264][265] - 公司2024年6月30日现金及等价物为11亿美元,较2023年12月31日增加5.17亿美元[267][268] - 公司经营活动现金流为2.307亿美元,较上年同期大幅改善[269] - 公司认为未来12个月内有足够资金维持持续经营[272] - 公司的可转换高级无担保票据具有固定利率,公司没有其他重大债务,因此认为借款活动不会面临重大利率风险[279]

In the latest market close, Novavax (NVAX) reached $12.57, with a -1.87% movement compared to the previous day. The stock's performance was behind the S&P 500's daily loss of 1.37%. On the other hand, the Dow registered a loss of 1.21%, and the technology-centric Nasdaq decreased by 2.3%.The vaccine maker's shares have seen an increase of 2.07% over the last month, surpassing the Medical sector's gain of 0.74% and the S&P 500's gain of 1.11%.Investors will be eagerly watching for the performance of Novavax ...

Vaccine manufacturer Novavax (NASDAQ:NVAX) is falling on Tuesday following a major sentiment downgrade. Indeed, analysts at JPMorgan warned that NVAX stock has exceeded the true value it can extract from its Covid-19 vaccine. As a result of the erosion of confidence, the market is severely penalizing shares today.According to Investing.com, NVAX stock dropped more than 8% in the premarket session before seeing losses accelerate after the opening bell. As of this writing, shares are down more than 25%. JPMor ...

peepoInvestment Overview I last provided coverage of Novavax (NASDAQ:NVAX) - the Gaithersburg, Maryland based developer of "innovative vaccines to prevent serious infectious diseases", ahead of the company's Q1 2024 earnings in early May. Frankly, I was not especially optimistic about the company's prospects, although I did not rule out a surprise - I wrote as follows: The days of wild share price fluctuations and spikes >$100 per share are a long way behind Novavax now - a spike into the double digi ...

Novavax (NVAX) has skyrocketed 211.2% in the year-to-date period against the industry’s 3.1% fall, as seen in the chart below. The stock also outperformed the sector and the S&P 500. Shares of the company are currently trading above its 200-day moving average.NVAX Stock Outperforms Industry, Sector & S&P 500 Image Source: Zacks Investment ResearchThis surge in share price can be attributed to Novavax’s recently signed multi-billion dollar deal with pharma giant Sanofi (SNY) to market its protein-based COVID ...